Dermira, Inc. will present data from its glycopyrronium tosylate (formerly DRM04) and Cimzia (certolizumab pegol) Phase 3 clinical programs in poster sessions at the 26th European Academy of Dermatology and Venereology (EADV) Congress, taking place in Geneva, Switzerland, September 13–17.
Newly reported data from the Phase 3 glycopyrronium tosylate clinical program will highlight the impact of primary axillary hyperhidrosis (excessive underarm sweating) on the daily lives of patients before and following four weeks of treatment with glycopyrronium tosylate. Glycopyrronium tosylate is designed to block sweat production by inhibiting the interaction between acetylcholine and the cholinergic receptors responsible for sweat gland activation.
Dermira and UCB will also present new 48-week clinical efficacy data and quality of life findings from the Phase 3 clinical program evaluating Cimzia in patients with moderate to severe chronic plaque psoriasis. Cimzia is not currently approved for the treatment of psoriasis by any regulatory authority worldwide.
“We are pleased to be presenting data that allow us to share the advancements made toward the treatment of skin conditions like plaque psoriasis and hyperhidrosis, which research shows can have a profound negative impact on a person’s overall quality of life,” said Eugene A. Bauer, M.D., chief medical officer of Dermira and a dermatologist. “The new findings that will be presented for the glycopyrronium tosylate and CIMZIA Phase 3 programs provide important new insights into how these potential treatment options could one day have both a meaningful clinical benefit and offer improvements in how patients manage these conditions.”Next Story